The number of adults overweight or obese in China is projected to reach 540 million and 150 million in 2030, potentially increasing competition and lowering prices for Novo Nordisk's drugs in the market.
Chinese drugmakers' generic versions of Novo Nordisk's products could lead to a price reduction of around 25% for semaglutide in China, impacting the market pricing dynamics significantly.
[
add
]
[
|
|
...
]